Faeth Therapeutics, Inc. (FTH)
| Market Cap | 516.55M +4,366.1% |
| Revenue (ttm) | n/a |
| Net Income | -211.36M |
| EPS | -24.64 |
| Shares Out | 25.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 237,064 |
| Open | 20.34 |
| Previous Close | 19.65 |
| Day's Range | 19.08 - 20.44 |
| 52-Week Range | 7.45 - 42.14 |
| Beta | -0.29 |
| Analysts | Strong Buy |
| Price Target | 55.31 (+176.69%) |
| Earnings Date | Nov 3, 2026 |
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for FTH stock is "Strong Buy." The 12-month stock price target is $55.31, which is an increase of 176.69% from the latest price.
News
Faeth Therapeutics price target lowered to $69 from $70 at Guggenheim
Guggenheim analyst Brad Canino lowered the firm’s price target on Faeth Therapeutics (FTH) to $69 from $70 and keeps a Buy rating on the shares as the firm adjusted estimates…
Faeth Therapeutics reports Q3 EPS (79c), consensus (71c)
“Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in…
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics Quarterly report: Q3 2026
Faeth Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Faeth Therapeutics Earnings release: Q3 2026
Faeth Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Faeth Therapeutics appoints Adam Schayowitz to board of directors
Faeth Therapeutics (FTH) announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymewor...
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics presents updated preclinical data on PIKTOR at ESMO
Faeth Therapeutics (FTH) announced presentation of preclinical data at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of mu...
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an ...
Faeth Therapeutics to present preclinical data on PIKTOR at ESMO 2026
Faeth Therapeutics (FTH) will present preclinical data at the European Society for Medical Oncology Congress 2026 in Madrid, Spain. The poster will be presented on Friday, October 23, and will…
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announ...
Faeth Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating. Faeth Therapeutics is an early clinical-stage oncology company developing novel therapies targeting the PI3K/AKT...
Faeth Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $40 price target
Faeth Therapeutics Transcript: KOL event
PIKTOR combines PI3Kα and mTORC1/2 inhibition to target a broad PAM-altered population, with management citing preclinical and early clinical activity plus tolerability data. PIK-201 top-line results are expected later in 2026, followed by initial PIK-101 data by year-end 2027.
Faeth Therapeutics Slides: KOL event
Faeth Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 6, 2026.
Faeth Therapeutics management to meet with Oppenheimer
Meeting to be held in New York on October 13 hosted by Oppenheimer.
Faeth Therapeutics names Karen Vousden to board of directors
Faeth Therapeutics (FTH) “announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026. Dr. Vousden is a cancer biologist recognized for her work…
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critic...
Faeth Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Multi-node inhibition of the PAM pathway is showing promising efficacy and tolerability, with oral regimens positioned as a major advantage. Key data in endometrial cancer are expected by year-end, with breast cancer and other solid tumor programs advancing. Intellectual property extends into the 2040s.
Faeth Therapeutics initiated with a Buy at Guggenheim ahead of de-risking data
As previously reported, Guggenheim initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target The firm, which views PIKTOR Phase 2 data in endometrial cancer due…
Faeth Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Brad Canino initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $70 price target
Faeth Therapeutics assumed with a Buy at Lucid Capital
Lucid Capital assumed coverage of Faeth Therapeutics (FTH) with a Buy rating and $59 price target The firm sees current share levels as offering an attractive risk/reward into the year-end…
Faeth Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Multi-node inhibition of the PI3K/AKT/mTOR pathway with oral agents shows promising efficacy and tolerability in early trials for endometrial and breast cancer. Upcoming data readouts and strategic combinations aim to address unmet needs and differentiate from existing therapies.
Faeth Therapeutics initiated with a Buy at TD Cowen
TD Cowen analyst Tara Bancroft initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and no price target PIKTOR is validated by the recent success of Revtorpyk and the…